SCHEMBL23900552

SCHEMBL23900552

COC(=O)c1nccn(C(C)C)c1=O

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 3/20 0.40
NPSR1 Q6W5P4 2/20 0.38
GAA P10253 1/20 0.36
ALDH1A1 P00352 4/20 0.35
POLB P06746 2/20 0.35
KMT2A Q03164 2/20 0.35
KDM4E B2RXH2 4/20 0.35
NPBWR1 P48145 1/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
JMJD6 Q6NYC1 1/20 0.33
TSHR P16473 2/20 0.32
HSD17B10 Q99714 1/20 0.32
PPARG P37231 1/20 0.32
MAPK10 P53779 1/20 0.32
RXFP1 Q9HBX9 1/20 0.32
NCOR2 Q9Y618 1/20 0.32
MAPK1 P28482 1/20 0.32
LMNA P02545 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23888693 0.81 HCAR3 (0.36) L3MBTL1NPSR1ALDH1A1KDM4ESMN1; SMN2
SCHEMBL23982866 0.80 ADORA2A (0.34) ALDH1A1KMT2ASMN1; SMN2LMNA
SCHEMBL23900733 0.78 SMN1; SMN2 (0.43) L3MBTL1NPSR1GAAALDH1A1POLB
SCHEMBL12410983 0.78 JMJD6 (0.35) L3MBTL1NPSR1ALDH1A1KDM4ESMN1; SMN2
SCHEMBL13153190 0.72 BRD4 (0.32) SMN1; SMN2
SCHEMBL71518 0.70 NPSR1 (0.59) L3MBTL1NPSR1GAAALDH1A1KDM4E
SCHEMBL21879900 0.70 NPSR1 (0.41) L3MBTL1NPSR1ALDH1A1KDM4EMAPK1
SCHEMBL3522370 0.69 L3MBTL1 (0.47) L3MBTL1NPSR1GAAALDH1A1POLB
SCHEMBL12890135 0.69 ALDH1A1 (0.47) ALDH1A1POLBKMT2AKDM4ETSHR
SCHEMBL30716516 0.69 KDM4E (0.54) L3MBTL1ALDH1A1POLBKMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250361223-A1 AMIDE COMPOUNDS AND USES THEREOF HUTCHISON MEDIPHARMA LTD (CN) 2025-11-27 US disclosed
US-12435062-B2 Amide compounds and uses thereof HUTCHISON MEDIPHARMA LIMITED (CN) 2025-10-07 US disclosed
CN-117777103-A Amide compound and application thereof 和记黄埔医药(上海)有限公司 2024-03-29 CN disclosed
CN-117720519-A Amide compound and application thereof 和记黄埔医药(上海)有限公司 2024-03-19 CN disclosed
CN-117720520-A Amide compound and application thereof 和记黄埔医药(上海)有限公司 2024-03-19 CN disclosed
CN-115315422-B Amide compound and application thereof 和记黄埔医药(上海)有限公司 2023-11-07 CN disclosed
US-20230174513-A1 AMIDE COMPOUNDS AND USES THEREOF HUTCHISON MEDIPHARMA LIMITED (CN) 2023-06-08 US disclosed
US-20230174513-A1 AMIDE COMPOUNDS AND USES THEREOF HUTCHISON MEDIPHARMA LIMITED (CN) 2023-06-08 US disclosed
US-20230174513-A1 AMIDE COMPOUNDS AND USES THEREOF HUTCHISON MEDIPHARMA LIMITED (CN) 2023-06-08 US disclosed
EP-4126844-A1 AMIDE COMPOUNDS AND USES THEREOF Hutchison Medipharma Limited (CN) 2023-02-08 EP disclosed
CN-115315422-A Amide compound and application thereof 和记黄埔医药(上海)有限公司 2022-11-08 CN disclosed
WO-2021197276-A1 Amide compounds and uses thereof HUTCHISON MEDIPHARMA LIMITED (CN) 2021-10-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230174513-A1 AMIDE COMPOUNDS AND USES THEREOF ASNS, ASS1, NAT1 L3MBTL1 4838/4885NPSR1 554/4885GAA 374/4885
US-12435062-B2 Amide compounds and uses thereof ASNS, ASS1, NAT1 L3MBTL1 4838/4885NPSR1 554/4885GAA 374/4885
US-20250361223-A1 AMIDE COMPOUNDS AND USES THEREOF ASNS, NAT1, AADAC L3MBTL1 4787/4885NPSR1 606/4885GAA 381/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.